1. Common targetable biomarkers in canine hemangiosarcoma and human angiosarcomaHuyen Thuc Tran Luong, Dominique Revets, Matteo De March, Sofie Vercammen, Hilde De Rooster, Ario De Marco, Antonio Cosma, 2024, objavljeni povzetek znanstvenega prispevka na konferenci Ključne besede: comparative oncology, angiosarcoma, hemangiosarcoma, nanobodies
Objavljeno v RUNG: 18.03.2025; Ogledov: 197; Prenosov: 0
Gradivo ima več datotek! Več... |
2. P856 : a single-cell functional precision medicine landscape of multiple myelomaKlara Kropivšek, Paul Kachel, Sandra Goetze, Rebekka Wegmann, Yannik Severin, Benjamin D. Hale, Yasmin Festl, Julien Mena, Audrey Van Drogen, Nadja Dietliker, 2022, objavljeni povzetek znanstvenega prispevka na konferenci Opis: Multiple myeloma (MM) is a cancer of plasma cells, defined by complex genetics and extensive intra- and inter-patient heterogeneity. Despite improved patient survival driven by a plethora of treatment options, the disease remains incurable.
Molecularly-guided precision medicine to individualize treatment strategies in MM has had limited success, in part due to the genetic and molecular complexity of the disease. Functional precision medicine, a complementary approach in which patient treatment is guided by the ex vivo drug response of patient cells, has not yet been evaluated for MM systematically.
Ključne besede: mutliple myeloma, hematology, precision medicine, microscopy, deep learning, phenotyping, oncology, proteotype
Objavljeno v RUNG: 11.11.2024; Ogledov: 594; Prenosov: 4
 Povezava na datoteko
Gradivo ima več datotek! Več... |
3. Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myelomaKlara Kropivšek, Paul Kachel, Sandra Goetze, Rebekka Wegmann, Yasmin Festl, Yannik Severin, Benjamin D. Hale, Julien Mena, Audrey Van Drogen, Nadja Dietliker, 2023, izvirni znanstveni članek Opis: Abstract
Multiple myeloma (MM) is a plasma cell malignancy defined by complex genetics and extensive patient heterogeneity. Despite a growing arsenal of approved therapies, MM remains incurable and in need of guidelines to identify effective personalized treatments. Here, we survey the ex vivo drug and immunotherapy sensitivities across 101 bone marrow samples from 70 patients with MM using multiplexed immunofluorescence, automated microscopy and deep-learning-based single-cell phenotyping. Combined with sample-matched genetics, proteotyping and cytokine profiling, we map the molecular regulatory network of drug sensitivity, implicating the DNA repair pathway and EYA3 expression in proteasome inhibitor sensitivity and major histocompatibility complex class II expression in the response to elotuzumab. Globally, ex vivo drug sensitivity associated with bone marrow microenvironmental signatures reflecting treatment stage, clonality and inflammation. Furthermore, ex vivo drug sensitivity significantly stratified clinical treatment responses, including to immunotherapy. Taken together, our study provides molecular and actionable insights into diverse treatment strategies for patients with MM.
Ključne besede: ultiple myeloma, precision medicine, ex-vivo, pharmacoscopy, proteotyping, oncology, hematology, microscopy, drug score
Objavljeno v RUNG: 11.11.2024; Ogledov: 615; Prenosov: 5
 Celotno besedilo (10,16 MB)
Gradivo ima več datotek! Več... |
4. |
5. |
